Pricing Log in Create free account

Braveheart Bio, Inc. (BRVE) vs Novavax, Inc. (NVAX)

Braveheart Bio, Inc. and Novavax, Inc. are both Biotechnology companies. Braveheart Bio, Inc. and Novavax, Inc. are of similar size ($1.6B and $1.6B). Braveheart Bio, Inc. has the higher net margin (0.00% vs −18.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 9 metrics below, Braveheart Bio, Inc. leads on 6 and Novavax, Inc. on 3.

Valuation

Metric BRVE NVAX Biotechnology median
P/E — n/m 10.60
P/S n/m 4.31 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 3.28 9.02
Earnings yield — (4.28%) (32.88%)
Free cash flow yield (16.31%) (13.87%) (23.13%)

Profitability

Metric BRVE NVAX Biotechnology median
Gross margin — 78.01% 68.51%
Operating margin 0.00% (21.23%) 0.00%
Net margin 0.00% (18.64%) 0.00%
Free cash flow margin 0.00% (58.05%) 0.00%
Return on equity 0.00% 41.08% (51.96%)
Return on assets 0.00% (7.42%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BRVE NVAX Biotechnology median
Revenue growth (TTM) — (61.33%) 6.76%
EPS growth (last fiscal year) — 309.76% 29.88%
Revenue growth, 5-year CAGR — 18.76% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BRVE NVAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 13.63 2.15 4.97
Net debt to EBITDA 1.34 (1.04) 1.01

Dividend

Metric BRVE NVAX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BRVE NVAX Biotechnology median
Market cap 1.57b 1.61b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack